99 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
48
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Array Biopharma
18
8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.
Array Biopharma
46
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
Array Biopharma
39
Discovery of 7-tetrahydropyran-2-yl chromans: -site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid -protein (A ) in the central nervous system.
Array Biopharma
20
Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.
Array Biopharma
18
Identification of a new class of glucokinase activators through structure-based design.
Array Biopharma
54
Spirocyclicß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloidß in a higher species.
Array Biopharma
31
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
Array Biopharma
31
Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors.
Array Biopharma
19
Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
Array Biopharma
2
The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Array Biopharma
27
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
Array Biopharma
30
Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
Array Biopharma
19
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
Array Biopharma
86
Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.
Array Biopharma
34
Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator.
Array Biopharma
21
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
Array Biopharma
10
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Array Biopharma
24
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Array Biopharma
1
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Array Biopharma
14
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Array Biopharma
25
Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Array Biopharma
21
The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
Array Biopharma
14
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.
Array Biopharma
8
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
Array Biopharma
69
Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Array Biopharma
30
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
Array Biopharma
194
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
Array Biopharma
114
Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
Array Biopharma
814
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
34
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
Array Biopharma
79
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
Array Biopharma
78
Compounds for the treatment of BRAF-associated diseases and disorders
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Array Biopharma
508
Bicyclic fused pyridine compounds as inhibitors of TAM kinases
Array Biopharma
188
Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases
Array Biopharma
556
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
157
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
Array Biopharma
812
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
31
Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds
Array Biopharma
83
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Array Biopharma
232
Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
60
Method of treatment using substituted imidazo[1,2b]pyridazine compounds
Array Biopharma
815
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
158
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
Array Biopharma
60
Method of treatment using substituted imidazo[1,2b]pyridazine compounds
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Array Biopharma
638
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
Array Biopharma
232
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
31
N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
Array Biopharma
232
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
60
Method of treatment using substituted imidazo[1,2b]pyridazine compounds
Array Biopharma
59
Method of treatment using substituted imidazo[1,2b]pyridazine compounds
Array Biopharma
83
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
Array Biopharma
232
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
215
4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
Array Biopharma
716
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
716
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
556
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
814
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
812
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
557
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
555
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Array Biopharma
60
Method of treatment using substituted imidazo[1,2B]pyridazine compounds
Array Biopharma
105
Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Array Biopharma
143
Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
Array Biopharma
165
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
Array Biopharma
233
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
715
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma